NZ748120A - Tri-segmented pichinde viruses as vaccine vectors - Google Patents
Tri-segmented pichinde viruses as vaccine vectorsInfo
- Publication number
- NZ748120A NZ748120A NZ748120A NZ74812017A NZ748120A NZ 748120 A NZ748120 A NZ 748120A NZ 748120 A NZ748120 A NZ 748120A NZ 74812017 A NZ74812017 A NZ 74812017A NZ 748120 A NZ748120 A NZ 748120A
- Authority
- NZ
- New Zealand
- Prior art keywords
- tri
- segment
- orf
- vaccine vectors
- pichinde virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- C12Q1/06—Quantitative determination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10051—Methods of production or purification of viral material
- C12N2760/10052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ788311A NZ788311A (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338400P | 2016-05-18 | 2016-05-18 | |
| PCT/EP2017/061865 WO2017198726A1 (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ748120A true NZ748120A (en) | 2025-08-29 |
Family
ID=58800799
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ748120A NZ748120A (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
| NZ788311A NZ788311A (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ788311A NZ788311A (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190135875A1 (enExample) |
| EP (1) | EP3458593A1 (enExample) |
| JP (3) | JP7254018B2 (enExample) |
| KR (2) | KR102671785B1 (enExample) |
| CN (2) | CN109804074B (enExample) |
| AU (2) | AU2017266738B2 (enExample) |
| BR (1) | BR112018073794A2 (enExample) |
| CA (1) | CA3023599A1 (enExample) |
| EA (1) | EA201892648A1 (enExample) |
| IL (2) | IL314272A (enExample) |
| MX (2) | MX2018013956A (enExample) |
| NZ (2) | NZ748120A (enExample) |
| SG (1) | SG11201810048VA (enExample) |
| WO (1) | WO2017198726A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2438773T3 (es) | 2007-12-27 | 2014-01-20 | Universität Zürich | Vectores arenavíricos defectuosos en la replicación |
| PL3077519T3 (pl) | 2013-12-03 | 2021-10-18 | Hookipa Biotech Gmbh | Szczepionki CMV |
| US10722564B2 (en) | 2014-11-13 | 2020-07-28 | Université de Genéve | Tri-segmented arenaviruses as vaccine vectors |
| CA2987155A1 (en) | 2015-06-10 | 2016-12-15 | Hookipa Biotech Ag | Hpv vaccines |
| IL314371A (en) | 2015-11-04 | 2024-09-01 | Hookipa Biotech Gmbh | Vaccines against hepatitis B virus |
| PT3373959T (pt) | 2015-11-12 | 2022-08-09 | Hookipa Biotech Gmbh | Partículas de arenavírus como vacinas contra o cancro |
| AU2018247958A1 (en) * | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| NZ783169A (en) | 2019-06-25 | 2024-12-20 | Gilead Sciences Inc | Flt3l-fc fusion proteins and methods of use |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| US20220380805A1 (en) | 2019-11-07 | 2022-12-01 | Universität Basel | Arenaviruses as vectors |
| EP4069729B1 (en) | 2019-12-06 | 2025-01-22 | Precision BioSciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| LT4081305T (lt) | 2019-12-24 | 2024-11-25 | Carna Biosciences, Inc. | Diacilglicerolio kinazę moduliuojantys junginiai |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| MX2022014725A (es) | 2020-05-29 | 2023-02-09 | Hookipa Biotech Gmbh | Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus. |
| JP7693813B2 (ja) | 2021-01-14 | 2025-06-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン及び使用方法 |
| US20240174724A1 (en) | 2021-03-23 | 2024-05-30 | Hookipa Biotech Gmbh | Arenaviruses used in treatments of prostate cancer |
| US20240269142A1 (en) | 2021-05-13 | 2024-08-15 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| US20240229073A1 (en) | 2021-05-13 | 2024-07-11 | Hookipa Biotech Gmbh | Arenaviruses as vectors |
| WO2022269362A2 (en) * | 2021-06-21 | 2022-12-29 | Vaxxinova International B.V. | Veterinary viral vector |
| CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CA3236106A1 (en) | 2021-11-08 | 2023-05-11 | Henning Lauterbach | Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| WO2007109812A2 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| US8173657B2 (en) | 2006-03-23 | 2012-05-08 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| ES2438773T3 (es) | 2007-12-27 | 2014-01-20 | Universität Zürich | Vectores arenavíricos defectuosos en la replicación |
| WO2014140301A1 (en) * | 2013-03-15 | 2014-09-18 | Université De Genève | Anti-mycobacterial vaccines |
| CN103224999B (zh) * | 2013-04-25 | 2015-11-18 | 中华人民共和国大榭出入境检验检疫局 | 检测沙粒病毒科病毒的简并引物及rt-pcr检测方法 |
| ES2746150T3 (es) | 2014-09-22 | 2020-03-04 | Univ Minnesota | Sistema de genética inversa para el virus Pichindé y métodos de uso |
-
2017
- 2017-05-17 IL IL314272A patent/IL314272A/en unknown
- 2017-05-17 NZ NZ748120A patent/NZ748120A/en unknown
- 2017-05-17 SG SG11201810048VA patent/SG11201810048VA/en unknown
- 2017-05-17 CA CA3023599A patent/CA3023599A1/en active Pending
- 2017-05-17 JP JP2019513483A patent/JP7254018B2/ja active Active
- 2017-05-17 CN CN201780044797.7A patent/CN109804074B/zh active Active
- 2017-05-17 AU AU2017266738A patent/AU2017266738B2/en active Active
- 2017-05-17 EA EA201892648A patent/EA201892648A1/ru unknown
- 2017-05-17 NZ NZ788311A patent/NZ788311A/en unknown
- 2017-05-17 CN CN202311410316.3A patent/CN117486979A/zh active Pending
- 2017-05-17 WO PCT/EP2017/061865 patent/WO2017198726A1/en not_active Ceased
- 2017-05-17 EP EP17726575.8A patent/EP3458593A1/en active Pending
- 2017-05-17 BR BR112018073794-1A patent/BR112018073794A2/pt active Search and Examination
- 2017-05-17 US US16/302,086 patent/US20190135875A1/en not_active Abandoned
- 2017-05-17 KR KR1020187036105A patent/KR102671785B1/ko active Active
- 2017-05-17 IL IL262963A patent/IL262963B2/en unknown
- 2017-05-17 KR KR1020247018106A patent/KR20240095333A/ko active Pending
- 2017-05-17 MX MX2018013956A patent/MX2018013956A/es unknown
-
2018
- 2018-11-14 MX MX2024005757A patent/MX2024005757A/es unknown
-
2022
- 2022-05-23 US US17/751,319 patent/US20220289797A1/en active Pending
- 2022-10-06 JP JP2022161464A patent/JP7547433B2/ja active Active
-
2023
- 2023-12-18 AU AU2023285703A patent/AU2023285703A1/en active Pending
-
2024
- 2024-08-28 JP JP2024146333A patent/JP2024170461A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018013956A (es) | 2019-07-04 |
| US20190135875A1 (en) | 2019-05-09 |
| CN109804074B (zh) | 2023-10-10 |
| NZ788311A (en) | 2025-11-28 |
| JP7254018B2 (ja) | 2023-04-07 |
| CN117486979A (zh) | 2024-02-02 |
| CN109804074A (zh) | 2019-05-24 |
| KR20190016032A (ko) | 2019-02-15 |
| JP2019516410A (ja) | 2019-06-20 |
| EA201892648A1 (ru) | 2019-06-28 |
| AU2023285703A1 (en) | 2024-01-18 |
| EP3458593A1 (en) | 2019-03-27 |
| US20220289797A1 (en) | 2022-09-15 |
| KR102671785B1 (ko) | 2024-06-04 |
| CA3023599A1 (en) | 2017-11-23 |
| KR20240095333A (ko) | 2024-06-25 |
| JP7547433B2 (ja) | 2024-09-09 |
| MX2024005757A (es) | 2024-05-24 |
| BR112018073794A2 (pt) | 2019-02-26 |
| AU2017266738A1 (en) | 2018-11-29 |
| WO2017198726A1 (en) | 2017-11-23 |
| JP2024170461A (ja) | 2024-12-10 |
| IL262963B2 (en) | 2025-01-01 |
| AU2017266738B2 (en) | 2023-10-12 |
| IL314272A (en) | 2024-09-01 |
| JP2023012463A (ja) | 2023-01-25 |
| SG11201810048VA (en) | 2018-12-28 |
| IL262963B1 (en) | 2024-09-01 |
| IL262963A (en) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005757A (es) | Virus pichinde de tres segmentos como vectores de vacunas. | |
| CY1123339T1 (el) | Τρι-τμηματικοι αρεναϊοι ως φορεις εμβολιου | |
| PH12018501047A1 (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| MX2023008067A (es) | Virus vaccinia atenuados competentes para replicacion con delecion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer. | |
| MX2018008413A (es) | Virus oncolitico modificado. | |
| MX2021001883A (es) | Virus recombinantes del mixoma y usos de los mismos. | |
| WO2015061294A3 (en) | Use of sting agonists to treat chronic hepatitis b virus infection | |
| PH12021553231A1 (en) | Hepatitis b core protein allosteric modulators | |
| PH12017500450A1 (en) | Flavivirus virus like particle | |
| EA201891975A1 (ru) | Тиазолидные соединения для лечения вирусных инфекций | |
| PH12016500465A1 (en) | Deoxynojirimycin derivatives and methods of their using | |
| PH12017500627A1 (en) | Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof | |
| PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
| MX376266B (es) | Particulas no replicantes derivadas de virus y sus usos. | |
| MX392311B (es) | Arbovirus recodificado y vacunas. | |
| MX354758B (es) | Metodos para la liberacion de las particulas similares a virus. | |
| EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
| EA201790771A1 (ru) | Фармацевтические композиции длительного действия для лечения гепатита c | |
| BR112017024786A2 (pt) | virus oncolíticos recombinantes e usos dos mesmos | |
| AR095118A1 (es) | Un procedimiento de inactivación viral en composición que comprende factor vii | |
| GB2547835A (en) | Protective material | |
| YANG et al. | Establishment of a EV71 virus infection model of tree shrew primary renal cells | |
| Kalla et al. | ASSESSMENT OFTHE VIABILITY OF THE COCCOID FORM OF HELICOBACTER PYLORI IN MICE | |
| MY185444A (en) | Enterovirus 71 antiviral peptides | |
| EA202191862A3 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения |